Siemens expands Gamma agreement:
This article was originally published in Clinica
Malvern, Pennsylvania-based subsidiary of Siemens Medical Solutions has gained exclusive worldwide marketing rights to Gamma Medica's molecular imaging product, X-Spect, following an extension of the original agreement in July which had restricted Siemens' rights to the US. X-Spect is a dual modality system for pre-clinical imaging, combining functional nuclear imaging technique with anatomical imaging provided by computed tomography. Since the two companies signed the deal, rocketing sales of X-Spect have led Gamma Medica, of Northridge, California, to record a 400% increase in revenues during its fiscal 2004.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.